Sign In   |   Register
News: Publications

NEW Consensus Statement: ESC/EAS on PCSK9 - Open Access

01 November 2016   (2 Comments)
Share |

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

A joint consensus statement from the European Society of Cardiology and the European Atherosclerosis Society Task Force.

Publication in full


Ulf Landmesser, M. John Chapman, Michel Farnier, Baris Gencer, Stephan Gielen, G. Kees Hovingh, Thomas F. Lüscher, David Sinning, Lale Tokgözoglu, Olov Wiklund, Jose Luis Zamorano, Fausto J. Pinto, and Alberico L. Catapano on behalf of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).


To be announced.


Administration says...
Posted 10 November 2016
Dear Andreea We are not in a position to answer this question, which would best be addressed to the drug company./EAS
andreea dumitrescu says...
Posted 10 November 2016
Are we allowed to change the treatment from one PCSK9 inhibitor to another one? .We have a pacient with FH, MI at 50 years of age who has been on treatment with atorvastatin 80 mg/day and ezetimibe 10 mg/day. Approximately a year ago he was included in the Pfizer study with bococizumab. On this treatment he still had LDLc of 110 mg/dl. The study has been stopped recently, so we thought about changing the pacient's treatment to evolocumab. Are there any imune reactions expexted?

Membership Software Powered by YourMembership  ::  Legal